GlassScriptPhysician profile
Nathan J Averill
NPI 1891824355
$25,450.91
in general payments reported to CMS, 2019-2025
66 companies · $2,919 in 2025
The $2,919 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $1,990 · 2021: $2,625 · 2022: $2,155 · 2023: $7,114 · 2024: $7,174 · 2025: $2,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,000 · Food and Beverage: $8,181 · Education: $26.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,000.00 |
| Food and Beverage | $8,181.41 |
| Education | $26.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,360.83 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,225.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,186.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,136.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $950.47 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $791.48 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $612.83 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Allergan, INC. | $567.92 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $531.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $454.89 | 2019-2025 | |
| Amgen INC. | $450.52 | 2019-2025 | Tepezza, Evenity, Prolia |
| Insulet Corporation | $396.21 | 2023-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $386.58 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $342.99 | 2023-2025 | Caplyta |
| Corium, LLC | $325.40 | 2022-2024 | Azstarys, Azstarys |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $320.94 | 2023-2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $320.62 | 2023-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Takeda Pharmaceuticals U.S.A., INC. | $320.38 | 2019-2023 | Trintellix |
| Abbott Laboratories | $293.32 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Janssen Pharmaceuticals, INC | $287.67 | 2019-2023 | Xarelto |
| Dexcom, INC. | $185.81 | 2023-2025 | Dexcom G6 Transmitter |
| Upsher-Smith Laboratories LLC | $182.29 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $181.34 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.41 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $168.44 | 2019-2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $165.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.21 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $112.01 | 2025 | Fanapt, Hetlioz |
| Astellas Pharma US INC | $109.49 | 2019-2025 | Veozah |
| Esperion Therapeutics, INC. | $107.72 | 2020-2023 | Nexletol |
| Nestle Healthcare Nutrition INC. | $97.03 | 2020-2022 | |
| Boston Scientific Corporation | $96.26 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Cequr Corporation | $95.35 | 2023-2025 | Cequr Simplicity |
| Supernus Pharmaceuticals, INC. | $94.72 | 2020-2024 | Qelbree, Qelbree |
| Corcept Therapeutics | $92.21 | 2024-2025 | Korlym |
| Antares Pharma, INC. | $90.64 | 2019-2025 | Xyosted |
| Eisai INC. | $87.05 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $83.98 | 2022-2024 | Quviviq |
| Seqirus USA INC | $67.75 | 2024-2025 | Fluad, Flucelvax |
| Amneal Pharmaceuticals LLC | $62.52 | 2023 | Lyvispah |
| Jazz Pharmaceuticals INC. | $60.87 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $58.75 | 2021 | |
| Lundbeck LLC | $56.50 | 2023 | Rexulti |
| Shire North American Group INC | $54.08 | 2019 | |
| Endo Pharmaceuticals INC. | $52.50 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.25 | 2022 | |
| Amarin Pharma, INC. | $46.22 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $41.15 | 2022-2023 | |
| Tris Pharma INC | $40.94 | 2023 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $40.44 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $32.10 | 2020 | |
| Alexion Pharmaceuticals, INC. | $26.29 | 2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $25.31 | 2025 | Yorvipath |
| Edwards Lifesciences Corporation | $22.19 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Horizon Therapeutics Plc | $21.44 | 2023 | Krystexxa |
| Therapeuticsmd, INC. | $19.24 | 2019 | |
| Nevro Corp. | $18.78 | 2024 | Senza |
| Ironshore Pharmaceuticals INC. | $16.65 | 2024 | |
| Philips North America LLC | $16.08 | 2025 | Vest Therapy Und |
| Alfasigma USA, INC. | $16.03 | 2020 | |
| Tolmar, INC. | $15.93 | 2023 | |
| Arbor Pharmaceuticals, INC. | $15.79 | 2019 | |
| Medtronic, INC. | $14.59 | 2025 | Minimed 780g |
| Currax Pharmaceuticals LLC | $13.42 | 2020 | |
| Mylan Specialty L.P. | $13.26 | 2020 | |
| Zyla Life Sciences, INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Averill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.